ABOS - CIK 0001576885
The table below shows Acumen Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$115.54M | -$86.22M | -$43.06M | -$35.15M | -$17.96M | -$7.45M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $133.93M | $48.03M | -$171.67M | $39.19M | -$104.12M | - |
| Dividends paid | - | - | - | - | - | - |
Acumen Pharmaceuticals, Inc. reported operating cash flow of -$115.54M for fiscal year 2025. That is down 34.0% from -$86.22M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$7.45M (FY 2020) to -$115.54M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$34.00K | $6.93M | $151.75M | $3.91M | $200.47M | $44.67M |